You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP inhibitor Resistant

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Prostate Cancer, Castration-resistant Prostate Cancer Trial in Washington, Baltimore (Olaparib, Vitamin C)

Not yet recruiting
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Washington, District of Columbia
  • +1 more
Aug 12, 2022

Prostate Cancer Trial in Ann Arbor, Detroit, Charlottesville (Olaparib, AZD6738)

Active, not recruiting
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +2 more
Jan 9, 2023

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 23, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Laboratory Biomarker Analysis, Olaparib,

Active, not recruiting
Has Results
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Laboratory Biomarker Analysis
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 19, 2022

Ovarian Tumor Trial in United States (Dostarlimab, Bevacizumab, Niraparib)

Completed
  • Ovarian Neoplasm
  • Birmingham, Alabama
  • +9 more
Feb 20, 2023

Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in United States

Suspended
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Phoenix, Arizona
  • +8 more
Jul 26, 2022

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in

Recruiting
  • Advanced Pancreatic Carcinoma
  • +27 more
  • Gainesville, Florida
  • +3 more
Jan 3, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Advanced Solid Tumor Trial (CVL218)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 9, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in United

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Laboratory Biomarker Analysis
  • +3 more
  • La Jolla, California
  • +21 more
Dec 2, 2022

High Grade Serous Carcinoma Trial in Baltimore, Boston, Philadelphia (Olaparib Pill, AZD6738)

Recruiting
  • High Grade Serous Carcinoma
  • Baltimore, Maryland
  • +2 more
Mar 4, 2022

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Prostate Cancer Metastatic Trial in Boston (Telaglenastat, Talazoparib)

Not yet recruiting
  • Prostate Cancer Metastatic
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 27, 2021